

Lung cancer study

A review article on lung cancer study

¹Ku. Papiha S. Tekade, ²Dr. Dipti B. Ruikar

Research scholar
Department of Pharmaceutical Quality Assurance
Amaravati, India.

Abstract-

Introduction: Lung cancer stands as the primary contributor to cancer-related years of life lost and bears the greatest economic impact compared to other malignancies. The pivotal role of research in enhancing outcomes for lung cancer patients cannot be overstated. This study unveils the findings from an extensive examination of worldwide lung cancer research spanning the decade from 2004 to 2013.[1]

Methods: The investigation employed bibliometric methods to conduct a quantitative assessment of research productivity across the top 24 countries in global cancer research. This assessment was based on articles and reviews retrieved from the Web of Science (WoS) database.

Results: The primary research areas identified were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Notably, there has been a shift towards an increased focus on basic science, accompanied by a decline in the output of clinical translational research during this period. In conclusion, our results highlight a substantial gap between the extensive health, social, and economic impact of lung cancer and the comparatively lower global research output in comparison to other cancer types. Additionally, there is a notable disparity in emphasis, with lesser commitment to diagnostics, screening, and quality of life research compared to basic science and medical research. These findings are anticipated to inform future cancer research initiatives in the field of lung cancer.

INTRODUCTION

Lung cancer stands as a prevalent and deadly malignancy in the developed world, causing over 40,000 annual deaths in the UK alone. While the incidence in men is decreasing, there is a rising trend in women, surpassing breast cancer rates in some countries. In developing nations with high smoking rates, mortality is expected to persistently increase. Despite the significant impact of lung cancer, the 5-year survival rate has seen minimal improvement since 1952. This series reviews the current state of lung cancer research, emphasizing the need for advancements in survival rates.


Smoking remains the primary cause, but only 10% of smokers develop lung cancer, highlighting the influence of genetic and dietary factors. Chemoprevention strategies gain importance due to the persistent challenge of eradicating smoking from society. Late-stage diagnosis contributes to poor survival rates, and population-based screening, though challenging, holds promise for early detection. Palliative treatments are advancing, offering improved survival and quality of life.

Molecular technologies provide insights into lung cancer's pathobiology, suggesting potential therapeutic strategies. The elderly face specific challenges, with myths affecting their treatment. Age should not hinder diagnosis and treatment, and limited surgical resection may benefit those with comorbidities. Despite a low rate of investigation and treatment in the UK, there is a call for properly resourced and staffed centers of excellence.

This review series aims to dispel pessimism surrounding lung cancer by addressing debates, controversies, and the need for widespread participation in research. Multicenter trials are crucial for raising standards of care, fostering optimism, and ultimately improving survival rates for lung cancer patients. Increased awareness and evidence-based knowledge are essential for progress in the diagnosis and management of this challenging disease.[2]

THERE ARE TWO MAIN TYPES OF LUNG CANCER:

There are two primary categories of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, a less prevalent form of lung cancer is referred to as carcinoid.



❖ SMALL CELL LUNG CANCER (SCLC)

There are two distinct subtypes of small cell lung cancer: small cell carcinoma and combined small cell/large cell cancer, also known as mixed small cell lung cancer. The nomenclature for these types is based on the specific cell characteristics observed under a microscope. Notably, small cell lung cancer is strongly correlated with cigarette smoking. Typically, chemotherapy serves as the primary treatment approach for small cell lung cancer.

❖ NON-SMALL CELL LUNG CANCER (NSCLC)

Non-small cell lung cancer is the more prevalent form, accounting for approximately 80 percent of lung cancer cases. This type of cancer generally exhibits a slower growth rate and a slower propensity to spread to other parts of the body compared to small cell lung cancer. Non-small cell lung cancer encompasses three primary subtypes:

❖ **Adenocarcinoma:** Typically located in the outer regions of the lung, this form of non-small cell lung cancer originates in the epithelial tissues, which line body cavities and surfaces, forming glands.

❖ **Squamous cell carcinoma:** Typically situated in the central lung near an air tube (bronchus), this non-small cell lung cancer variant is characterized by its location.

❖ **Large cell carcinoma:** This subtype of non-small cell lung cancer can manifest in any part of the lung and tends to exhibit a faster growth and spread rate compared to adenocarcinoma or squamous cell carcinoma.

While the mentioned subtypes are the most common, a microscopic examination of your lung cancer tumor may provide more specific details about its subtype. Collaborate with your doctor to gain a precise understanding of the type of lung cancer you have and how it influences your available treatment options.

❖ TYPES OF TREATMENT

Lung cancer treatment varies based on the cancer type and its stage. Non-small cell lung cancer can be addressed through surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these methods. On the other hand, small cell lung cancer is typically treated with a combination of radiation therapy and chemotherapy.

➤ Here is a breakdown of the treatment options:

❖ **Surgery:** Involves the removal of cancerous tissue through an operation.

❖ **Chemotherapy:** Utilizes specialized medications to shrink or eliminate cancer. These drugs can be administered orally, intravenously, or through a combination of both.

❖ **Radiation Therapy:** Involves the use of high-energy rays, similar to X-rays, to eliminate cancer cells.

❖ **Targeted Therapy:** Deploys drugs to impede the growth and spread of cancer cells. Prior to this treatment, tests are conducted to determine its suitability for the specific type of cancer.

Lung cancer is often addressed through collaborative efforts of medical professionals from various specialties. Pulmonologists specialize in lung diseases, surgeons perform operations, with thoracic surgeons focusing on chest, heart, and lung surgeries. Medical oncologists treat cancer with medications, while radiation oncologists employ radiation for cancer treatment.

❖ CAUSES

The primary cause of the majority of lung cancers is smoking, impacting both active smokers and individuals exposed to second hand smoke. However, lung cancer can also manifest in non-smokers and those with minimal second-hand smoke exposure, presenting cases where the precise cause is unclear.

The mechanism by which smoking induces lung cancer involves the damage to lung cell linings. Inhaling cigarette smoke introduces a plethora of cancer-causing substances, or carcinogens, leading to immediate changes in lung tissue. Initially, the body may attempt to repair this damage, but with each subsequent exposure, the normal cells lining the

lungs endure increasing harm. Over time, this cumulative damage results in abnormal cellular behavior, potentially culminating in the development of cancer.

❖ RISK FACTORS

Several factors can elevate your susceptibility to lung cancer. Certain risk factors, like smoking, are within your control and can be mitigated by quitting. Conversely, there are factors beyond your control, such as family history, that contribute to the risk of lung cancer.

❖ RISK FACTORS FOR LUNG CANCER INCLUDE:

- ❖ **Smoking:** The risk of developing lung cancer rises in correlation with both the number of cigarettes smoked daily and the duration of smoking. Quitting smoking at any age significantly reduces the likelihood of lung cancer.
- ❖ **Exposure to Second-hand Smoke:** Non-smokers also face an increased risk of lung cancer when exposed to second-hand smoke.
- ❖ **Previous Radiation Therapy:** Individuals who have undergone chest radiation therapy for another form of cancer may have an elevated risk of developing lung cancer.
- ❖ **Exposure to Radon Gas:** Radon, a byproduct of the natural breakdown of uranium in soil, rock, and water, can reach unsafe levels in buildings, including homes, posing a potential risk for lung cancer.
- ❖ **Exposure to Asbestos and Carcinogens:** Occupational exposure to carcinogenic substances like asbestos, arsenic, chromium, and nickel, particularly in conjunction with smoking, can heighten the risk of lung cancer.
- ❖ **Family History of Lung Cancer:** Individuals with a family history of lung cancer, involving a parent, sibling, or child, are at an increased risk of developing the disease.

❖ COMPLICATIONS

- ❖ Lung cancer can lead to various complications, including:
 - ❖ **Shortness of breath:** The growth of cancer blocking major airways can result in difficulty breathing. Additionally, lung cancer may cause the accumulation of fluid around the lungs, hindering the affected lung's full expansion during inhalation.
 - ❖ **Coughing up blood:** Lung cancer may induce bleeding in the airway, leading to the coughing up of blood (hemoptysis). Severe bleeding can occur, but treatments are available to manage and control it.
 - ❖ **Pain:** Advanced lung cancer that spreads to the lung lining or other areas, such as bones, can cause pain. Inform your doctor about any pain experienced, as there are numerous treatments available to alleviate it.
 - ❖ **Fluid in the chest (pleural effusion):** Lung cancer can result in the accumulation of fluid around the affected lung in the chest cavity (pleural space), causing shortness of breath. Treatments exist to drain the fluid and reduce the likelihood of pleural effusion recurrence.
 - ❖ **Metastasis (cancer spreading to other parts of the body):** Lung cancer commonly metastasizes to organs like the brain and bones, leading to symptoms such as pain, nausea, and headaches. Once lung cancer has spread beyond the lungs, it is generally not curable. However, treatments are available to manage symptoms and enhance overall survival.

❖ PREVENTION

While there is no foolproof way to prevent lung cancer, you can lower your risk by taking the following measures:

- ❖ **Avoid Smoking:** If you've never smoked, refrain from starting, and engage in conversations with your children to educate them about the risks associated with smoking. Initiate discussions about the dangers early on to equip them with the knowledge to resist peer pressure.
- ❖ **Quit Smoking:** Cease smoking immediately, as quitting significantly reduces your risk of lung cancer, even if you've been a long-term smoker. Consult your doctor for strategies, stop-smoking aids, such as nicotine replacement products or medications, and consider joining support groups for added assistance.
- ❖ **Minimize Secondhand Smoke Exposure:** Encourage smokers in your vicinity to quit, or at the very least, request them to smoke outdoors. Steer clear of smoke-filled areas, such as bars and restaurants, and opt for smoke-free alternatives.
- ❖ **Test for Radon:** Assess the radon levels in your home, especially if you reside in an area known for radon issues. High radon levels can be addressed to enhance the safety of your home. For information on radon testing, reach out to your local department of public health or the American Lung Association.

❖ **Mitigate Workplace Carcinogen Exposure:** Take precautions at work to shield yourself from exposure to harmful chemicals. Adhere to your employer's safety guidelines, such as wearing a face mask if provided. Consult your doctor for additional measures to protect yourself at work, as smoking amplifies the risk of lung damage from workplace carcinogens.

❖ **Adopt a Nutrient-Rich Diet:** Embrace a healthy diet rich in fruits and vegetables, obtaining vitamins and nutrients primarily from food sources. Avoid excessive vitamin intake through supplements, as high doses may pose harm. For instance, a study on heavy smokers administering beta carotene supplements to reduce lung cancer risk revealed an increased risk of cancer.

❖ **Engage in Regular Exercise:** Initiate regular exercise, starting at a comfortable pace if you are not already active. Aim for physical activity on most days of the week to promote overall well-being.

❖ **EMERGING APPROACHES OF LUNG CANCER:**

Currently, lung cancer contributes to 23% of overall cancer-related deaths, surpassing the combined mortality rates of breast cancer, colon cancer, and prostate cancer. [3,4]. The high fatality associated with lung cancer is attributed to the absence of early diagnostic methods, with nearly 50% of cases being diagnosed at stage IV, resulting in limited prospects for survival [5].

The challenge in treating lung cancer is compounded by the difficulty of reaching the deeper sections of the lung through conventional therapeutic approaches. [6]. Lung cancer occurrence is generally categorized into two main histological types based on appearance: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC, although less prevalent, is characterized by heightened aggressiveness, often resulting in an average survival of four months if untreated. [7]. Its profound fatality stems from its rapid growth, early metastasis, and swift metabolism. SCLC originates from neuroendocrine tumors and, as a result, is adorned with neurosecretory vesicles and neurofilaments. [8]. Constituting approximately 80% to 85% of lung cancers, NSCLC is resistant to traditional chemotherapy and radiation therapy. NSCLC can be subcategorized into epidermoid, large cell, broncho-alveolar, adenocarcinoma, and squamous cell carcinoma. [9]. Each histological subtype within NSCLC exhibits unique characteristics and responds differently to specific treatments. The primary cause of both SCLC and NSCLC has been attributed to tobacco smoking, as the pulmonary system is exposed to mutagenic agents present in inhaled smoke. [10]. The sole subtype of lung cancer not linked to smoking is adenocarcinoma, originating from exposure to occupational and environmental carcinogens like radon, asbestos, and various forms of radiation. Additionally, less common instigators of lung cancer include familial predisposition, genetic alterations (alk, met, ros1 genes, etc.), and *Helicobacter pylori* infection. [11,12].

❖ **CONCLUSIONS:**

In conclusion, our findings underscore a significant disparity in international research output between lung cancer and other malignancies, despite the substantial health, social, and economic impact associated with lung cancer. Particularly concerning is the observed decline in research commitment (RC) to lung cancer in the majority of the 24 leading research-active countries, potentially affecting the clinical outcomes that research endeavors can achieve. This trend emerges at a crucial juncture when opportunities abound for a deeper understanding of the disease. The reduction in smoking rates in high-resource countries offers a chance to explore alternative risk factors, while the escalating incidence of lung cancer in lower-resource nations provides an opportunity to study the emerging epidemic using advanced technologies.

Addressing the challenges of late-stage diagnosis, there is a pressing need to prioritize lung cancer research comprehensively, with a specific emphasis on areas like diagnosis and screening. Notably, there is a discernible shift from clinical research toward basic science, highlighting the importance of fostering translational research. Encouraging such translational efforts is vital to ensuring that high-quality basic research translates into innovative developments, ultimately improving outcomes for a disease with persistently poor survival rates.

❖ **ABBREVIATION:**

Wos - Web of Science

SCLC: small cell lung cancer.

NSCLC: non-small cell lung cancer.

REFERENCES:

1. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. *Thorax*. 2000 Dec 1;55(12):987-99. Sutherland G. Current approaches to the management of smoking cessation. *Drugs*. 2002 Dec;62:53-61.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA: a cancer journal for clinicians*. 2011 Mar;61(2):69-90.

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA: a cancer journal for clinicians*. 2011 Mar;61(2):69-90.
4. Hansen RN, Zhang Y, Seal B, Ryan K, Yong C, Darilay A, Ramsey SD. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis. *BMC cancer*. 2020 Dec;20:1-6.
5. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. *Science*. 1997 Jun 20;276(5320):1868-72.
6. Ahmad J, Akhter S, Rizwanullah M, Amin S, Rahman M, Ahmad MZ, Rizvi MA, Kamal MA, Ahmad FJ. Nanotechnology-based inhalation treatments for lung cancer: state of the art. *Nanotechnology, science and applications*. 2015 Nov 19:55-66.
7. Sukumar UK, Bhushan B, Dubey P, Matai I, Sachdev A, Packirisamy G. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. *International Nano Letters*. 2013 Dec;3(1):45.
8. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. *Harrison's principles of internal medicine, 19e*. New York, NY, USA:: McGraw-hill; 2015.
9. Moss WT, Cox JD. *Moss' radiation oncology: rationale, technique, results*. (No Title). 1994.
10. Witschi H, Espiritu I, Dance ST, Miller MS. A mouse lung tumor model of tobacco smoke carcinogenesis. *Toxicological Sciences*. 2002 Aug 1;68(2):322-30.
11. Johnston L. *Lung Cancer: Making Sense of Diagnosis, Treatment, and Options*. O'Reilly; 2001.